Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan
Authors' conclusion
In routine clinical practice, biosynthetic semaglutide was associated with clinically meaningful improvements in glycaemic control, body weight and physical quality of life. The safety profile remained consistent with established semaglutide therapy.
Study context
- Population
- Adults with T2D initiating biosynthetic semaglutide in routine outpatient care in a cost-constrained setting, Pakistan
- Participants
- 217 adults
- Outcome
- Change in HbA1c from baseline to end of study (EOS)
- Follow-up
- 30 weeks (EOS)
Methodological detailsmulticentre, non-interventional, 30-week
- Multicentre
- Non-interventional
- 30-week
Main finding
As reported in the abstract
HbA1c · baseline to EOS
Mean HbA1c baseline
9.27%
Mean HbA1c at end of study (EOS)
7.41%
Change in HbA1c (p < 0.001)
−1.86%
Observational data: associations, not effects.
Secondary outcomes
HbA1c targets · EOS
- Achieved HbA1c < 8.0%
- 76.6%
- Achieved HbA1c < 7.0%
- 38.7%
Body weight · EOS
- Mean body weight change (p < 0.001)
- −7.84 kg
- Achieved ≥ 5% weight loss
- 76.5%
BMI and waist circumference
- Significant reductions in BMI and waist circumference
Patient-reported outcomes
- Treatment satisfaction and physical quality of life improved significantly
Safety
Adverse events
- Severe hypoglycaemic episodes
- 0
- AEs predominantly non-serious and gastrointestinal
Original publication
Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes Obes Metab. Published 28 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →